Paper Review Records
All Paper Review Records
6 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study
Ibuki Tsuru; Satoru Taguchi; Ryo Tanaka; Taketo Kawai; Tomoyuki Kaneko; Yu Nakamura; Yoshifumi Miyauchi; Hayato Hoshina; Daisuke Obinata; Masashi Koshiba; Masashi Shiozaki; Jun Takahashi; Masato Kano; Akihiro Naito; Shohei Suda; Michio Noda; Nozomi Sugiyama; Takehiro Tanaka; Yukari Uemura; Jimpei Miyakawa; Jun Kamei; Shigenori Kakutani; Aya Niimi; Yuta Yamada; Yusuke Sato; Yukio Yamada; Hiroaki Nishimatsu; Takashi Murata; Sayuri Takahashi; Tappei Takada; Yoshiyuki Akiyama; Satoru Takahashi; Tetsuya Fujimura; Hiroshi Fukuhara; Tohru Nakagawa; Haruki KumeShow moreShow less
1. Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 2. Department of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan; 3. Department of Urology, Teikyo University School of Medicine, Tokyo, Japan; 4. Department of Urology, Kyorin University School of Medicine, Tokyo, Japan; 5. Department of Urology, Jichi Medical University, Tochigi, Japan; 6. Department of Urology, Nihon University School of Medicine, Tokyo, Japan; 7. Department of Urology, Shinshu University School of Medicine, Nagano, Japan; 8. Department of Urology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan; 9. Department of Urology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan; 10. Department of Urology, The Fraternity Memorial Hospital, Tokyo, Japan; 11. Department of Urology, Musashino Red Cross Hospital, Tokyo, Japan; 12. Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan; 13. Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan; 14. Department of Urology, Tokyo Metropolitan Tama Medical Center, Fuchu, JapanShow moreShow less
Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery
Go Makimoto; Toshio Kubo; Isao Oze; Kadoaki Ohashi; Katsuyuki Hotta; Masahiro Tabata; Junichi Soh; Shinichi Toyooka; Kuniaki Katsui; Nagio Takigawa; Mitsune Tanimoto; Katsuyuki KiuraShow moreShow less
1. Department of Allergy and Respiratory Medicine, Okayama University Hospital; 2. Center for Clinical Oncology, Okayama University Hospital, Okayama; 3. Division of Molecular & Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya; 4. Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama; 5. Department of Thoracic Surgery, Okayama University Hospital; 6. Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; 7. Department of General Internal Medicine 4, Kawasaki Hospital, Kawasaki Medical School, Okayama; 8. Department of Hematology, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, JapanShow moreShow less
The effect of escalating the boost dose for patients with involved resection margin after breast-conserving surgery
Sunmin Park; Seung Do Ahn; Eun Kyung Choi; Su Ssan KimShow moreShow less
1. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaShow moreShow less
Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors
Yoko Yamada; Hirofumi Mukai; Yuta Tokudome; Motoko Kaneko; Kosuke Kashiwabara; Noriaki WadaShow moreShow less
1. Department of Breast Oncology, Saitama Cancer Center, Saitama; 2. Department of Breast and Medical Oncology, National Cancer Center Hospital East, Chiba; 3. Department of Pharmacy, Kyoundo Hospital, Tokyo; 4. Department of Pharmacy, Yamagata University Hospital, Yamagata; 5. Department of Biostatistics, School of Public Health, Graduate School of Medicine, the University of Tokyo, Tokyo; 6. Department of Surgery, Tokyo Dental College Ichikawa General Hospital, Chiba, JapanShow moreShow less
Atypical radiological presentation of pulmonary invasion of diffuse large B-cell lymphoma mimicking Pneumocystis jiroveci pneumonia
Ryoko Inaba Higashiyama; Shinichi Makita; Akiko Miyagi Maeshima; Dai MaruyamaShow moreShow less
1. Department of Hematology, National Cancer Center Hospital; 2. Department of Pathology, National Cancer Center Hospital, Tokyo, JapanShow moreShow less
Maintenance hormonal therapy after treatment with medroxyprogesterone acetate for patients with atypical polypoid adenomyoma
Hidetaka Nomura; Yuko Sugiyama; Terumi Tanigawa; Maki Matoda; Sanshiro Okamoto; Kohei Omatsu; Hiroyuki Kanao; Kazuyoshi Kato; Kuniko Utsugi; Nobuhiro TakeshimaShow moreShow less
1. Department of Gynecology, Cancer Institute Hospital, Tokyo, JapanShow moreShow less
FAQ
How long does JAPANESE JOURNAL OF CLINICAL ONCOLOGY take to review a manuscript?
As of 2026-11-19, CrushSCI has 6 complete review records for JAPANESE JOURNAL OF CLINICAL ONCOLOGY. The fastest paper went from submission to acceptance in 34 days (Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study, received 2026-05-22, accepted 2026-06-25); the slowest took 173 days. The average is 101.5 days and the median is 115.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
